MCL Literature Feed

NCCN guidelines now highlight BTK inhibitor-based regimens as effective options for high-risk, TP53-mutated classical mantle cell lymphoma, formalizing a key strategy for this difficult-to-treat population.

Acalabrutinib plus rituximab successfully resolved paraneoplastic glomerulonephritis in an MCL patient, offering a new treatment approach for this rare renal complication.

The EHA-EU MCL network published comprehensive guidelines standardizing risk-stratified diagnosis and treatment for MCL, covering young/fit and elderly patients in both frontline and relapsed/refractory settings.

Light-chain-restricted hematogones in bone marrow can mimic MCL on flow cytometry, creating a significant diagnostic pitfall that could lead to misdiagnosis or incorrect staging assessments.

In newly diagnosed MCL, ATM deletion predicts shorter progression-free survival in TP53 wild-type patients, whereas ATM mutation may indicate a better prognosis, highlighting their distinct prognostic roles.

All BTK inhibitors impair platelet aggregation in MCL as a class effect, regardless of BTK specificity or dose, providing a clear mechanism for the bleeding risk seen with these agents.

Preclinical research shows ibrutinib inhibits poxvirus replication by targeting BTK, suggesting a potential secondary antiviral benefit for immunocompromised MCL patients receiving this therapy.

Single-cell analysis reveals pre-existing minor clones with unique mutations drive relapse, explaining patient-specific progression and the need to target intratumoral heterogeneity at diagnosis.

High-throughput sequencing accurately identifies IGHV somatic hypermutation status, a key prognostic biomarker in MCL, even in complex, multi-clonal samples, improving risk stratification and MRD tracking.

This transcriptomic study uses mantle cell lymphoma as a comparator to define effusion-based lymphoma as a distinct, post-germinal center entity driven by chronic inflammatory signaling pathways.

A novel 3D bioprinted hydrogel model improves primary MCL cell survival ex vivo, offering a more physiologically relevant platform for preclinical drug screening and studying the tumor microenvironment.

ctDNA sequencing in relapsed/refractory MCL identifies SMARCA4 and TP53 mutations as response predictors and offers more sensitive MRD monitoring than qPCR, improving non-invasive risk stratification.

Ibrutinib can cause rare but severe hepatic subcapsular hematomas in relapsed MCL; ultrasound is a key tool for early diagnosis and monitoring of this bleeding complication.

Comprehensive cfDNA analysis non-invasively tracks MCL disease burden and detects high-risk mutations, offering a powerful liquid biopsy tool for monitoring and risk stratification.

BRG1-driven suppression of ferroptosis is a key mechanism of BTKi resistance in MCL, and pharmacologic BRG1 inhibition restores BTKi sensitivity, suggesting a new combination therapy.

Cyclin D1 overexpression induces replication stress and a dependency on POLQ-mediated DNA repair, identifying POLQ inhibition as a novel, targeted therapeutic strategy for mantle cell lymphoma.

Nodal MCL with leukemic presentation is a high-risk subtype characterized by SOX11-negativity, increased TP53 alterations, and inferior overall survival, requiring distinct clinical consideration.

Real-world data on commercially insured B-cell NHL patients, including MCL, reveals a 48% relapse rate at 12 months post-CAR-T, with subsequent therapies incurring significant patient out-of-pocket costs.

This review argues that new agents like BTKi are disrupting the frontline MCL standard of care, challenging ASCT's role and demanding personalized, risk-adapted treatment guidelines to resolve clinical uncertainty.

Digital analysis of p53 immunohistochemistry establishes specific cut-offs (e.g., >50% for 2+/3+ nuclei) that reliably identify TP53 mutations and predict worse survival, improving rapid risk stratification.

This review summarizes the integration of BTK inhibitors into frontline MCL therapy and the emerging role of MRD, providing a treatment algorithm for managing newly diagnosed patients.

A rare case of composite CLL/MCL highlights diagnostic challenges from overlapping immunophenotypes, reinforcing the critical need for molecular and cytogenetic studies like FISH for t(11;14) for definitive diagnosis.

This case report of an 80-year-old man with MCL presenting with severe hyperleukocytosis (>491x10^9/L) highlights the diagnostic challenge of differentiating this rare presentation from other leukemias.

In elderly, frontline MCL, this SHINE secondary analysis shows achieving a complete response is critical for long-term PFS, and adding ibrutinib to BR significantly increases CR rates.

This is the first study from North India providing real-world evidence that rituximab maintenance improves overall and event-free survival in MCL, validating this standard of care in an underrepresented population.

Retrospective data show B symptoms and CBV conditioning negatively impact survival post-ASCT in MCL, supporting BeEAM conditioning and risk-adapted strategies for consolidation.

This case report highlights the risk of life-threatening invasive aspergillosis in an elderly MCL patient with chronic neutropenia, underscoring the need for high clinical suspicion for fungal infections.

This phase II trial protocol compares chemo-free ibrutinib/venetoclax/rituximab versus ibrutinib-chemoimmunotherapy in treatment-naive elderly MCL, aiming to establish a new frontline standard.

Serum beta-2 microglobulin is a critical prognostic biomarker in lymphoma, including MCL, where it reflects tumor burden and is a key component of the MIPI risk score.

This case series reports fatal Hepatitis B reactivation with ibrutinib and breakthrough reactivation on zanubrutinib despite prophylaxis, highlighting the need for vigilant HBV monitoring with all BTKis.